Key Points

New directions Lower urinary tract sensation and contractility are mediated by a multitude of mechanisms and receptors. Some of these are being investigated as potential targets for novel oral therapies for OAB; Altering afferent bladder signaling may be a novel approach to OAB therapy; Agonists and inhibitors of pain and mechanotransduction receptors such as TRPV and cannabinoid receptors are currently in preclinical and clinical studies and have shown some promise in certain patient populations.